source
- British biotech T-Therapeutics raises $133 million Series B to advance bispecific T-cell engagersT-Therapeutics, a British biotech, announced a $133 million Series B financing to advance its next-generation T-cell engager therapeutics. The round was co-led by Advent Life Sciences and the Brit…
- Evommune pays $30 million upfront to license Hinova’s oral molecular glue degrader for autoimmune pipelineEvommune announced a deal with Hinova Pharmaceuticals to license an oral molecular glue degrader aimed at autoimmune diseases. The agreement includes a $30 million upfront payment, split into $20…